Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Estimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis.

Kohn CG, Sidovar MF, Kaur K, Zhu Y, Coleman CI.

Health Qual Life Outcomes. 2014 May 5;12:66. doi: 10.1186/1477-7525-12-66.

2.

Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients.

Sidovar MF, Limone BL, Lee S, Coleman CI.

BMJ Open. 2013 May 28;3(5). pii: e002798. doi: 10.1136/bmjopen-2013-002798.

3.

Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort.

Sidovar MF, Limone BL, Coleman CI.

Patient Relat Outcome Meas. 2016 Feb 3;7:13-8. doi: 10.2147/PROM.S96956. eCollection 2016.

4.

Determination of minimum clinically important difference in pain, disability, and quality of life after extension of fusion for adjacent-segment disease.

Parker SL, Mendenhall SK, Shau D, Adogwa O, Cheng JS, Anderson WN, Devin CJ, McGirt MJ.

J Neurosurg Spine. 2012 Jan;16(1):61-7. doi: 10.3171/2011.8.SPINE1194. Epub 2011 Sep 30.

PMID:
21962034
5.

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.

Coteur G, Feagan B, Keininger DL, Kosinski M.

Aliment Pharmacol Ther. 2009 May 1;29(9):1032-41. doi: 10.1111/j.1365-2036.2009.03966.x.

6.

The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.

Hawton A, Green C, Telford CJ, Wright DE, Zajicek JP.

Mult Scler. 2012 Jun;18(6):853-61. doi: 10.1177/1352458511429319. Epub 2011 Nov 22.

PMID:
22108867
7.

Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD.

Zanini A, Aiello M, Adamo D, Casale S, Cherubino F, Della Patrona S, Raimondi E, Zampogna E, Chetta A, Spanevello A.

Respir Care. 2015 Jan;60(1):88-95. doi: 10.4187/respcare.03272. Epub 2014 Oct 21.

8.

Clinical importance of steps taken per day among persons with multiple sclerosis.

Motl RW, Pilutti LA, Learmonth YC, Goldman MD, Brown T.

PLoS One. 2013 Sep 4;8(9):e73247. doi: 10.1371/journal.pone.0073247. eCollection 2013.

9.

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.

Limone BL, Sidovar MF, Coleman CI.

Health Qual Life Outcomes. 2013 Jun 26;11:105. doi: 10.1186/1477-7525-11-105.

10.
11.

An analysis of Euroqol EQ-5D and Manchester Oxford Foot Questionnaire scores six months following podiatric surgery.

Maher AJ, Kilmartin TE.

J Foot Ankle Res. 2012 Jul 9;5(1):17. doi: 10.1186/1757-1146-5-17.

12.

Determination of minimum clinically important difference (MCID) in pain, disability, and quality of life after revision fusion for symptomatic pseudoarthrosis.

Parker SL, Adogwa O, Mendenhall SK, Shau DN, Anderson WN, Cheng JS, Devin CJ, McGirt MJ.

Spine J. 2012 Dec;12(12):1122-8. doi: 10.1016/j.spinee.2012.10.006. Epub 2012 Nov 14.

PMID:
23158968
13.

The multiple sclerosis rating scale, revised (MSRS-R): development, refinement, and psychometric validation using an online community.

Wicks P, Vaughan TE, Massagli MP.

Health Qual Life Outcomes. 2012 Jun 18;10:70. doi: 10.1186/1477-7525-10-70. Erratum in: Health Qual Life Outcomes. 2013;11:60.

14.

A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease.

Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, Vasoo S, Li SC, Thumboo J.

J Rheumatol. 2003 Oct;30(10):2268-74.

PMID:
14528528
15.

Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study.

Baert I, Freeman J, Smedal T, Dalgas U, Romberg A, Kalron A, Conyers H, Elorriaga I, Gebara B, Gumse J, Heric A, Jensen E, Jones K, Knuts K, Maertens de Noordhout B, Martic A, Normann B, Eijnde BO, Rasova K, Santoyo Medina C, Truyens V, Wens I, Feys P.

Neurorehabil Neural Repair. 2014 Sep;28(7):621-31. doi: 10.1177/1545968314521010. Epub 2014 Feb 6.

PMID:
24503204
16.

Mobility, walking and physical activity in persons with multiple sclerosis.

Kohn CG, Coleman CI, Michael White C, Sidovar MF, Sobieraj DM.

Curr Med Res Opin. 2014 Sep;30(9):1857-62. doi: 10.1185/03007995.2014.921147. Epub 2014 May 29.

PMID:
24803286
17.

Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study.

Grandy S, Fox KM; SHIELD Study Group.

Health Qual Life Outcomes. 2012 Aug 21;10:99. doi: 10.1186/1477-7525-10-99.

18.

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A.

Br J Rheumatol. 1997 May;36(5):551-9.

PMID:
9189057
19.

Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D.

Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N.

Mult Scler. 2013 Aug;19(9):1190-6. doi: 10.1177/1352458512474860. Epub 2013 Feb 11.

PMID:
23401128
20.

Health status and costs of ambulatory patients with multiple sclerosis in Hungary.

Péntek M, Gulácsi L, Rózsa C, Simó M, Iljicsov A, Komoly S, Brodszky V.

Ideggyogy Sz. 2012 Sep 30;65(9-10):316-24.

PMID:
23126217

Supplemental Content

Support Center